Nachrichten zur Karolinska Development AB Aktie

Karolinska Developments portfolio company SVF Vaccines appoints Dr Gaston Picchio as acting CEO

STOCKHOLM, Sweden, 15 November 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company SVF Vaccines has…

Interim Report - January-September 2024

STOCKHOLM – 15 November 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-September 2024. The…

Karolinska Development’s portfolio company BOOST Pharma successfully completes pre-IND meeting with FDA and receives second tranche of investment

STOCKHOLM, SWEDEN, November 5 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has…

Karolinska Development’s portfolio company Umecrine Cognition presents new preclinical Parkinson’s data on golexanolone at the scientific conference, INBC 2024

STOCKHOLM, SWEDEN – October 17, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition…

Karolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of fracture rates in children with rare bone disease

STOCKHOLM, SWEDEN, September 17 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has…

Interim Report - January-June 2024

STOCKHOLM – 30 August 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-June 2024. The…

Karolinska Development’s portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone

STOCKHOLM, SWEDEN – July 10, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition…

Karolinska Development invests in BOOST Pharma, expanding its portfolio

STOCKHOLM, SWEDEN – May 28, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the company has invested in…

Karolinska Development’s Annual General Meeting 2024

STOCKHOLM, SWEDEN – May 16, 2024. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held the Annual General Meeting…

Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC

STOCKHOLM, SWEDEN – May 8, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition…

Interim Report - January-March 2024

STOCKHOLM – 26 April 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-March 2024. The…

Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC

STOCKHOLM, SWEDEN – March 22, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition…

Karolinska Development Annual Report 2023 published

STOCKHOLM, SWEDEN – March 22, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2023.…

Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units

STOCKHOLM, Sweden, March 14 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Biosergen has published a…

Karolinska Development’s portfolio company Umecrine Cognition presents preclinical Parkinson’s data on golexanolone at AD/PD

STOCKHOLM, SWEDEN – March 6, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition…

AnaCardio receives second tranche of SEK 50 million, completing the previously announced Series A round

PRESS RELEASE Stockholm, Sweden, January 17, 2024 AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients…

Karolinska Developments portfolio company OssDsign expects fourth-quarter revenues to exceed market estimates

STOCKHOLM, SWEDEN, December 6, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that the portfolio company OssDsign expects revenues for…

Karolinska Development’s portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration

STOCKHOLM, SWEDEN, December 4, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company PharmNovo’s drug candidate…

Karolinska Development’s portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis

STOCKHOLM, SWEDEN – November 28, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition…

Karolinska Development’s portfolio company Umecrine Cognition raises additional funding for the clinical development of golexanolone

STOCKHOLM, SWEDEN – November 17, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition…

Interim Report - January-September 2023

STOCKHOLM – 17 November 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-September 2023. The…

Karolinska Developments portfolio company Modus Therapeutics raises capital to expand the development program for sevuparin

STOCKHOLM, SWEDEN November 8, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has…

Karolinska Development’s portfolio company PharmNovo reports positive results from a clinical phase 1 study of drug candidate PN6047

STOCKHOLM, SWEDEN, October 2, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company PharmNovo has successfully completed…

Karolinska Development’s portfolio company PharmNovo reports promising preclinical results on abuse potential and withdrawal symptom relief for its candidate drug PN6047

STOCKHOLM, SWEDEN, September 28, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company PharmNovo has reported promising…

Karolinska Developments portfolio company OssDsign raises SEK 150 million and makes strategic move to become a pure play orthobiologics company

STOCKHOLM, SWEDEN, September 27, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign successfully has completed…

Interim Report - January-June 2023

STOCKHOLM – 25 August 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-June 2023. The…

Covid-19 vaccine that can cope with mutated viruses in clinical phase 1 study at Karolinska University Hospital

A new DNA-based vaccine against covid-19 is being tested for the first time on healthy participants at Karolinska University Hospital.…

New method reveals bacterial reaction to antibiotics in five minutes

Researchers at Karolinska Institutet in Sweden have developed a molecular method able to detect whether or not bacteria respond to…

New study explains how a common virus can cause multiple sclerosis

Researchers at Karolinska Institutet in Sweden have found further evidence for how the Epstein-Barr virus can trigger multiple sclerosis or…

Karolinska University Hospital adopts strategy for nursing

To strengthen the hospital in leadership, innovation, continuous improvement, and professional development, Karolinska is establishing a strategy for nursing. To strengthen…

Neogap expands team with software expert to drive cancer immunotherapy innovation

Swedish biotech company Neogap Therapeutics has recruited bioinformatics and software development expert Alejandro Fernandez Woodbridge to strengthen the development of…

Prostatype Genomics publishes Annual Report for 2022

Prostatype Genomics AB today publishes the Annual Report for the financial year of 2021. The Annual Report is attached as…

Notice of Annual General Meeting in Karolinska Development AB (publ)

The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are invited to the Annual…

BioStock: BrainCool and KI conduct major cardiac arrest study

BrainCool will deliver its products RhinoChill and BrainCool System to Karolinska Institutet for a large international clinical study pre-hospital cooling…

NOTICE OF ANNUAL GENERAL MEETING

Shareholders in H & M Hennes & Mauritz AB (publ) (556042-7220) are hereby invited to the annual general meeting (AGM)…

Karolinska Development Annual Report 2022 published

STOCKHOLM, SWEDEN – March 24, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2022....…

Ghrelin treatment in heart failure patients showed increased contractility of the heart

AnaCardio´s founder Prof Lars Lund and colleagues from The Karolinska Institutet publish study on ghrelin treatment in patients with heart…

Regional ECT, lithium, and clozapine use linked to lower suicide rates in male adolescents

A new study from Karolinska Institutet suggests that electroconvulsive therapy (ECT), lithium, and clozapine may reduce suicide rates in adolescent…

Wilhelmina Hoffman and Fredrik Lundberg made honorary doctors at Karolinska Institutet

Karolinska Institutet has decided to make Wilhelmina Hoffman, specialist in geriatric medicine, and economist Fredrik Lundberg honorary doctors. The formal…

Internet treatment program to prevent child sexual abuse launched in several languages

Following a successful pilot study, an online anonymous treatment program aimed at reducing child sexual abuse by providing treatment to…

Pia Baumann takes up her position as Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…

Year-end Report - January-December 2022

STOCKHOLM – 17 February 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report - January-December 2022. The…

Storytel appoints Anna Etzler as SVP Operations

Anna Etzler joins Storytel as SVP Operations to lead the global Operations function as well as a business-wide Project Management…

dpa-AFX ProFeed